First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083763" target="_blank" >RIV/00023001:_____/23:00083763 - isvavai.cz</a>

Výsledek na webu

<a href="https://journals.lww.com/transplantjournal/Fulltext/2023/02000/First_Booster_of_SARS_COV_2_mRNA_Vaccine_Is_Not.40.aspx" target="_blank" >https://journals.lww.com/transplantjournal/Fulltext/2023/02000/First_Booster_of_SARS_COV_2_mRNA_Vaccine_Is_Not.40.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/TP.0000000000004421" target="_blank" >10.1097/TP.0000000000004421</a>

Jazyk výsledku

angličtina

Název v původním jazyce

First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft

Popis výsledku v původním jazyce

Background: Booster doses of mRNA SARS-CoV-2 vaccines have been widely administered to kidney transplant recipients (KTRs). However, there is a scarcity of safety data as KTRs have been excluded from vaccine clinical trials. The objective of this prospective, observational study is the evaluation of the safety of the first booster dose of mRNA vaccine in 108 virus-naive KTRs.Methods: Samples were obtained on the day of booster vaccination and subsequently three months later. Anti-HLA antibodies, donor-derived cell-free DNA (dd-cfDNA), clinical adverse events, and SARS-CoV-2 IgG antibodies were evaluated.Results: We detected no significant safety signals in KTRs after the booster dose. De novo donor-specific (DSA) anti-HLA antibody was detected in just a single case. There was no increase in anti-HLA antibodies mean fluorescence intensity (MFI), immunodominant antibodies MFI or calculated panel-reactive antibodies following the booster (p&gt;0.9 for all tests, respectively). A principal component analysis on anti-HLA antibodies showed a significant overlap between the two measurements and no differential clustering, PERMANOVA analysis revealed no significant differences between the two measurements (p&gt;0.999). There was no significant increase of dd-cfDNA above the 1% threshold in any KTR and, similarly, there was no overall increase in dd-cfDNA levels following the booster (p=0.427). There were no differences in eGFR before and after the booster, and no graft rejection was observed following vaccination. After the third dose, seroconversion was found in 80.6% KTRs.Conclusions: The first booster dose of mRNA SARS-CoV-2 vaccine is not associated with an increased risk of alloreactivity and sub/clinical kidney allograft injury (NCT05483725).

Název v anglickém jazyce

First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft

Popis výsledku anglicky

Background: Booster doses of mRNA SARS-CoV-2 vaccines have been widely administered to kidney transplant recipients (KTRs). However, there is a scarcity of safety data as KTRs have been excluded from vaccine clinical trials. The objective of this prospective, observational study is the evaluation of the safety of the first booster dose of mRNA vaccine in 108 virus-naive KTRs.Methods: Samples were obtained on the day of booster vaccination and subsequently three months later. Anti-HLA antibodies, donor-derived cell-free DNA (dd-cfDNA), clinical adverse events, and SARS-CoV-2 IgG antibodies were evaluated.Results: We detected no significant safety signals in KTRs after the booster dose. De novo donor-specific (DSA) anti-HLA antibody was detected in just a single case. There was no increase in anti-HLA antibodies mean fluorescence intensity (MFI), immunodominant antibodies MFI or calculated panel-reactive antibodies following the booster (p&gt;0.9 for all tests, respectively). A principal component analysis on anti-HLA antibodies showed a significant overlap between the two measurements and no differential clustering, PERMANOVA analysis revealed no significant differences between the two measurements (p&gt;0.999). There was no significant increase of dd-cfDNA above the 1% threshold in any KTR and, similarly, there was no overall increase in dd-cfDNA levels following the booster (p=0.427). There were no differences in eGFR before and after the booster, and no graft rejection was observed following vaccination. After the third dose, seroconversion was found in 80.6% KTRs.Conclusions: The first booster dose of mRNA SARS-CoV-2 vaccine is not associated with an increased risk of alloreactivity and sub/clinical kidney allograft injury (NCT05483725).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

<a href="/cs/project/NU22-C-126" target="_blank" >NU22-C-126: Aspekty imunitní odpovědi a efektivita posilující dávky mRNA vakcíny proti SARS-CoV-2 u nemocných po transplantaci ledviny</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transplantation

ISSN

0041-1337

e-ISSN

1534-6080

Svazek periodika

107

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

"e62"-"e64"

Kód UT WoS článku

000923643000005

EID výsledku v databázi Scopus

2-s2.0-85147047106